Latest News
AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.
Via The Motley Fool · October 12, 2026
Anduril is stealthily becoming a key producer of U.S. Navy submarines -- and also not so stealthily.
Via The Motley Fool · October 12, 2026
Investors weren't cheered by a major change in the company's leadership.
Via The Motley Fool · October 12, 2026
Paulo Roberto Simoes Da Cunha expanded his direct stake by 22%, bringing total holdings to ~265,000 shares at $17.98 per share.
Via The Motley Fool · October 12, 2026
Don't let shortsighted sellers distract you from this coin's real value.
Via The Motley Fool · October 12, 2026
An analyst made a significant price target cut.
Via The Motley Fool · October 12, 2026
One trades at half the earnings multiple of the other, but profitability and risk profiles tell starkly different stories.
Via The Motley Fool · October 12, 2026
The manufacturing leader is driving growth across multiple dimensions.
Via The Motley Fool · October 12, 2026
Don't get caught off guard by the impact of a higher income.
Via The Motley Fool · October 12, 2026
These companies have a long history of dividend growth.
Via The Motley Fool · October 12, 2026
Insider buying increased direct holdings to 264,605 shares, a 22% boost to prior equity exposure. The preferred stock traded at $17.98 per share during the acquisition, well above the $3.43 market close for common shares that same day.
Via The Motley Fool · October 12, 2026
The Ark Invest CEO has a lofty forecast for SpaceX.
Via The Motley Fool · October 12, 2026
Archer pursues Boeing partnerships to scale manufacturing, while Joby leverages early revenue from its Blade acquisition, but both burn cash at an alarming rate.
Via The Motley Fool · October 12, 2026
Split $10,000 between Alphabet and Nvidia today, and by 2030 that bet touches everything from search ads to robotaxis to quantum chips.
Via The Motley Fool · October 12, 2026
A pair of financial companies is apparently trying to acquire it.
Via The Motley Fool · October 12, 2026
Today, Oct. 12, 2026, premarket reports of acquisition discussions with GTCR and Elliott pushed the insurance-software provider higher as investors await deal confirmation.
Via The Motley Fool · October 12, 2026
De Oliveira more than doubled his direct stake, raising his exposure to the financial services giant after a modest 5% stock return over the past year.
Via The Motley Fool · October 12, 2026
The bull market may be running out of steam.
Via The Motley Fool · October 12, 2026
On Oct. 12, 2026, investors brace for bank earnings while semiconductor weakness pressures the broader market.
Via The Motley Fool · October 12, 2026
On Oct. 12, 2026, the AI infrastructure operator reportedly signed a multiyear agreement with Anthropic, reinforcing its pivot away from legacy mining operations.
Via The Motley Fool · October 12, 2026
Shares in the premium credit card business are down 18% in 2026.
Via The Motley Fool · October 12, 2026
Today, Oct. 12, 2026, takeover speculation evaporated after Starbucks ruled out a deal, sending the fast-casual chain down 3.75%.
Via The Motley Fool · October 12, 2026
Curaleaf looks eager to buy Aurora Cannabis, and that's helped to drive its value up.
Via The Motley Fool · October 12, 2026
A nice boost won't change the two problems that retirees will likely face.
Via The Motley Fool · October 12, 2026
Firefly trades at a fraction of AST's valuation multiple, but both burn cash at scale, here's which bet suits your risk appetite.
Via The Motley Fool · October 12, 2026